Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications.
Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals Incorporated (VRTX) is a trending stock: Facts to know before betting on it
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Vertex Inc. (NASDAQ:VERX) is one of the best beaten down stocks to invest in according to analysts. On December 5, Vertex Inc ...
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
Sundar Pichai introduced Vertex AI to the world during the Google I/O 2021 conference last year, placing it against managed AI platforms such as Amazon Web Services (AWS) and Azure in the global AI ...
Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind it? This article will walk you through what the numbers are really saying ...
Vertex Pharmaceuticals' core business is still firing on all cylinders. The biotech is expanding into other areas and diversifying its portfolio. Shares of Vertex look too attractive to pass up right ...
Vertex Pharmaceuticals (NASDAQ: VRTX) has been a big disappointment for investors in 2021. While the S&P 500 index soared nearly 30%, Vertex's shares are down 5%. Investors are much more focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback